Sustained release pharmaceutical composition
US5614487A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 28, 1993 |
| Grant date | Mar 25, 1997 |
| Priority date | — |
| Expiry date | May 28, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/61
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present document discloses the formation of imine adducts, preferably between a primary amine of a biologically active polypeptide and a reactive aldehyde group of a physiologically acceptable carrier. The imine adduct of human growth hormone and dextran is specifically described. These adducts serve to release the biologically active polypeptide via the reversible reaction in the formation of the imine adduct bond. These adducts have a surprising degree of stability that permits the use of the complex as a sustained release preparation. A key advantage of this technology is that after hydrolysis the complex releases the unmodified pharmaceutical. Thus, these adducts can be used as pharmaceutical compositions useful for the sustained release of the biologically active polypeptide over a predetermined, desired period of time.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.